# psoriasis - glm-5.2

- Benchmark system: raw
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4460
- Completion tokens: 3461
- Reasoning tokens: 
- Total tokens: 7921
- API requests reported: 
- Elapsed seconds: 394.644
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: Zhipu AI

---
Based on the provided transcriptomic data comparing psoriatic lesional skin to normal control skin, here is a multidimensional, evidence-grounded biological interpretation.

### 1. Overall Biological Interpretation

The transcriptomic profile of these psoriatic lesional skin samples is overwhelmingly dominated by a robust type-17 immune response, profound epidermal barrier remodeling, and active antimicrobial defense. The upregulation of specific interleukin cytokines (IL36A, IL36G, IL20, IL19, IL26), their downstream signaling regulators, and a dense cluster of chemokines and alarmins reveals a tissue environment actively driving pathogenic inflammation. Concurrently, the massive upregulation of skin differentiation complex (SDC) genes—specifically the SPRR family, late cornified envelope (LCE) genes, and S100 proteins—indicates a hyperproliferative state attempting to reinforce the physical epidermal barrier. The data also reveal a striking secondary metabolic and lipid-processing program, likely reflecting the altered biochemical environment of the psoriatic plaque. 

### 2. Core Biological Programs

**Program 1: IL-17/IL-36 Immune Signaling Network**
*   **Direction:** Upregulated
*   **Major supporting genes:** IL36A, IL36G, IL36RN, IL19, IL20, IL26, TNIP3, IRAK2
*   **Standardized Pathway:** Hallmark: Inflammatory Response; KEGG: Cytokine-cytokine receptor interaction
*   **Explanation:** The concomitant upregulation of IL36A/G (agonists) and IL36RN (antagonist) indicates a highly active, tightly balanced IL-36 signaling axis, which is known to upstream regulate IL-23/Th17 pathways in psoriasis. IL19 and IL20 are canonical downstream targets of IL-17 signaling in keratinocytes. TNIP3 and IRAK2 are key regulators of NF-κB and Toll-like/IL-1 receptor signaling, supporting active innate immune amplification.
*   **Evidence & Limitations:** Direct evidence from the input dataset is extremely strong (log2FC 2.08 to 11.37, FDR < 1e-62). This is established disease biology. A limitation is that transcript levels do not confirm functional protein secretion or cleavage of the IL-36 pro-forms.

**Program 2: Epidermal Differentiation and Barrier Reinforcement**
*   **Direction:** Upregulated
*   **Major supporting genes:** SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3, LCE3A, LCE3D, KRT6A
*   **Standardized Pathway:** GO: Epidermis development; GO: Cornified envelope assembly
*   **Explanation:** The small proline-rich proteins (SPRRs) and late cornified envelope (LCE) genes are cross-linking components of the cornified envelope. Their massive, coordinated upregulation reflects the keratinocyte hyperproliferation and altered differentiation typical of psoriatic plaques. KRT6A is a hallmark marker of psoriatic keratinocyte injury and hyperproliferation.
*   **Evidence & Limitations:** Strong direct evidence in the dataset (log2FC 3.99 to 8.29, FDR < 1e-62). Tissue-specific expression strongly matches this finding. A limitation is the potential confounding by tissue composition (see Section 6); these signals may simply reflect an increase in the absolute number of differentiating keratinocytes per biopsy rather than a per-cell upregulation.

**Program 3: Alarmin and Antimicrobial Defense**
*   **Direction:** Upregulated
*   **Major supporting genes:** S100A7, S100A7A, S100A8, S100A12, DEFB4A, DEFB4B, PI3
*   **Standardized Pathway:** GO: Defense response to fungus; GO: Antimicrobial humoral response
*   **Explanation:** S100 proteins and beta-defensins are alarmins and antimicrobial peptides secreted by stressed keratinocytes. They act as chemoattractants for neutrophils and T cells. Their extreme upregulation (e.g., S100A12 log2FC 8.32, DEFB4A log2FC 11.18) confirms the innate immune defense component of psoriatic skin.
*   **Evidence & Limitations:** Strong dataset evidence. Literature evidence strongly supports these as diagnostic biomarkers for psoriasis. Limitation: broad alarmin pathways are upregulated in many inflammatory dermatoses, limiting their specificity to psoriasis alone.

**Program 4: Immune Cell Recruitment and Vasculature Remodeling**
*   **Direction:** Upregulated
*   **Major supporting genes:** CXCL13, CXCR2, WNT5A, GPR15LG
*   **Standardized Pathway:** Reactome: Chemokine receptor binding; Hallmark: Angiogenesis
*   **Explanation:** CXCL13 and CXCR2 indicate active recruitment of specific immune cell subsets (B cells/Tfh cells for CXCL13; neutrophils for CXCR2). WNT5A is a critical driver of dermal angiogenesis, a key feature supporting the hyperproliferative psoriatic epidermis by increasing vascular supply.
*   **Evidence & Limitations:** Strong statistical evidence. A limitation is that single-cell resolution is lost in bulk RNA-seq, meaning the cellular source of these signals (keratinocytes vs. stromal cells vs. infiltrating leukocytes) must be inferred rather than measured directly.

**Program 5: Lipid Metabolism and Retinoic Acid/Aldehyde Processing**
*   **Direction:** Mixed (Mostly Upregulated)
*   **Major supporting genes:** AKR1B10, AKR1B15, FABP5, CYP2W1 (downregulated), UGT3A2 (downregulated)
*   **Standardized Pathway:** GO: Lipid metabolic process; Retinol metabolism
*   **Explanation:** The upregulation of aldo-keto reductases (AKR1B10/15) and fatty acid binding proteins (FABP5) indicates altered lipid handling in the psoriatic epidermis. The downregulation of CYP2W1 and UGT3A2 suggests a suppression of specific oxidative/conjugative metabolism. This may reflect a metabolic shift away from normal epidermal differentiation towards a proliferative, inflammatory state.
*   **Evidence & Limitations:** Moderate evidence; the directionality is mixed. Pathway/ontology evidence relies on multiple genes. This represents an exploratory biological program rather than a core established hallmark of psoriasis.

### 3. Key Genes and Interaction Modules

1.  **IL36G / IL36A / IL36RN Module:** 
    *   **Direction:** Upregulated (IL36G log2FC 5.68, IL36A log2FC 11.37, IL36RN log2FC 3.00).
    *   **Role:** Core drivers of Program 1.
    *   **Nature of relationship:** *Pathway co-membership and regulatory interaction.* IL36A/G bind to the IL-36 receptor, while IL36RN acts as a competitive antagonist at the same receptor. This indicates a tightly co-regulated signaling module.
2.  **S100A7 / S100A7A / S100A12:**
    *   **Direction:** Upregulated (log2FC 7.09 to 8.32).
    *   **Role:** Core effectors of Program 3.
    *   **Nature of relationship:** *Co-expression and pathway co-membership.* These genes are clustered in the Epidermal Differentiation Complex (EDC) on chromosome 1 and are co-expressed in response to IL-17A/F.
3.  **SPRR2 Cluster (SPRR2A, B, D, E, F, G):**
    *   **Direction:** Upregulated (log2FC 3.99 to 7.31).
    *   **Role:** Structural components for Program 2.
    *   **Nature of relationship:** *Co-expression.* Highly coordinated transcriptional upregulation of cross-linking proteins required for the psoriatic cornified envelope.
4.  **CXCL13 / CXCR2:**
    *   **Direction:** Upregulated (CXCL13 log2FC 5.89, CXCR2 log2FC 2.70).
    *   **Role:** Effectors of Program 4.
    *   **Nature of relationship:** *Pathway co-membership*. While they chemotactically signal to different cells (CXCL13 for B/T cells, CXCR2 ligands for neutrophils), together they define the immune infiltrate landscape of the lesional skin.
5.  **DEFB4A / DEFB4B:**
    *   **Direction:** Upregulated (log2FC > 11.0).
    *   **Role:** Antimicrobial defense in Program 3.
    *   **Nature of relationship:** *Direct physical interaction / Co-expression*. DEFB4A and DEFB4B historically refer to the same beta-defensin locus and its pseudogene/variant; their identical statistical profiles strongly suggest co-expression from a single genomic block.
6.  **AKR1B10 / AKR1B15:**
    *   **Direction:** Upregulated (~5-6 log2FC).
    *   **Role:** Metabolic reprogramming in Program 5.
    *   **Nature of relationship:** *Co-expression and pathway co-membership*. Both are aldo-keto reductases likely acting on similar lipid/aldehyde substrates in the inflamed keratinocytes.

### 4. Validation Priorities

**Priority 1: Mechanistic hypothesis - The IL-36/IL-17 Feed-Forward Loop**
*   **Why prioritize:** IL36A/G are among the most highly upregulated genes. Validating their role could confirm a key driver of the disease state.
*   **Dataset evidence:** Extreme statistical significance (FDR < 1e-90).
*   **External evidence:** Extensive literature supports IL-36 driving psoriasis-like dermatitis independently of IL-23.
*   **Next step:** Single-cell RNA-seq or RNAscope on lesional skin to determine if IL36G is expressed by keratinocytes and if IL36RN is upregulated in a compensatory manner by the same or adjacent cells.
*   **Conclusion status:** Established evidence.

**Priority 2: Therapeutic target - Targeting WNT5A-Driven Angiogenesis**
*   **Why prioritize:** Current psoriasis biologics target immune cytokines, but refractory cases often have persistent vascular changes.
*   **Dataset evidence:** WNT5A is upregulated (log2FC 2.52, FDR 1.04e-67).
*   **External evidence:** WNT5A is known to promote dermal microvascular endothelial cell migration.
*   **Next step:** Evaluate WNT5A protein expression in the dermal papillae versus keratinocytes via immunofluorescence; test WNT inhibitors in organotypic psoriatic skin models.
*   **Conclusion status:** Supported hypothesis.

**Priority 3: Biomarker - Circulating S100A12**
*   **Why prioritize:** S100A12 is an alarmin that can be released systemically.
*   **Dataset evidence:** Very high upregulation (log2FC 8.32).
*   **External evidence:** S100A proteins are investigated as serum biomarkers for psoriasis severity (PASI score).
*   **Next step:** Correlate serum S100A12 levels with lesional skin expression and clinical severity in a longitudinal cohort.
*   **Conclusion status:** Supported hypothesis.

**Priority 4: Interaction / network hypothesis - Altered Barrier Cross-Linking**
*   **Why prioritize:** The sheer number of SPRR genes upregulated suggests a shift in the protein composition of the cornified envelope.
*   **Dataset evidence:** 7 SPRR genes upregulated with FDR < 1e-62.
*   **External evidence:** SPRR proteins are heavily involved in cross-linking via transglutaminases.
*   **Next step:** Proteomic analysis of the cornified envelope in psoriatic vs. normal stratum corneum to confirm if the increased SPRR transcripts translate into altered structural protein composition.
*   **Conclusion status:** Exploratory hypothesis.

**Priority 5: Confounding or composition check - Keratinocyte Hyperproliferation vs. Tissue Composition**
*   **Why prioritize:** As a bulk RNA-seq dataset, the massive upregulation of keratinocyte genes (SPRRs, KRT6A) could simply reflect an increased ratio of epidermis to dermis in the lesional biopsy, rather than hyperactivation of individual cells.
*   **Dataset evidence:** Broad upregulation of keratinocyte structural genes.
*   **External evidence:** Psoriatic skin features acanthosis (thickening of the epidermis).
*   **Next step:** Normalize gene expression data to housekeeping genes specific to different cell types, or apply computational deconvolution (e.g., CIBERSORTx) to adjust for variable epidermal thickness across samples.
*   **Conclusion status:** Exploratory hypothesis.

### 5. Evidence Grounding and Independence

*   **Direct evidence from the input dataset:** The conclusions regarding the direction and magnitude of gene expression changes are backed by extremely strong statistical evidence (all listed genes have FDR < 1e-60).
*   **Disease-association evidence:** The presence of IL36G, S100A7, IL20, and KRT6A serves as highly specific internal validation that the tissue is indeed psoriatic. This is **genuinely independent evidence** confirming sample identity and disease state.
*   **Expression or tissue-specific evidence:** The upregulation of LCE3D and SPRR3 perfectly matches the tissue context (stratified squamous epithelium). This is confirmatory but not mechanistically independent.
*   **Pathway / ontology evidence:** The co-occurrence of cytokines and structural proteins supplies the biological pathway grounding. The pathway evidence largely overlaps with direct dataset evidence (i.e., the pathways light up specifically because these canonical genes are in the dataset).
*   **Genetic or clinical evidence:** Insufficient evidence in the provided table to determine genetic causality or specific clinical subtypes (e.g., psoriatic arthritis vs. cutaneous only). All associations must be treated as correlative.

### 6. Limitations and Alternative Explanations

1.  **Tissue or cell-composition differences:** Bulk RNA-seq captures an average signal across all cell types. The upregulation of immune genes (CXCL13, CXCR2) may partly reflect increased infiltration of leukocytes, while barrier genes reflect acanthosis. *Investigation:* Spatial transcriptomics or single-cell RNA-seq should be used to map these signals to specific cellular niches.
2.  **Association-versus-causation ambiguity:** While IL36A/G are highly upregulated, the dataset cannot prove they initiate the disease rather than acting as downstream amplifiers.
3.  **Disease severity and treatment exposure:** The input table does not specify whether these are treatment-naive lesions or from patients on systemic therapy. Treatment exposure can drastically alter chemokine and alarmin networks, serving as a major confounding variable.
4.  **Downregulated lncRNAs and pseudogenes:** Multiple genes with negative log2FC are uncharacterized (LOC105371988, LOC107984452, WAKMAR1). Their downregulation may be biologically significant, but they are systematically ignored in the primary interpretation due to the **insufficient evidence** regarding their mechanism of action.
5.  **Batch or platform effects:** Without access to the raw count matrix or metadata regarding sample processing, the extreme magnitude of some log2FC values (>11) could theoretically be influenced by transcript length biases or batch effects in alignment/quantification, though the internal consistency suggests the biology is highly dominant.
